Literature DB >> 24762331

Acanthosis nigricans in obese Chinese children.

H Y Ng1, Jack H M Young1, K F Huen1, Louis T W Chan1.   

Abstract

OBJECTIVES. To investigate the demographic characteristics and insulin resistance in local overweight/obese Chinese children with and without acanthosis nigricans, and the associations of acanthosis nigricans with insulin resistance and other cardiometabolic co-morbidities. DESIGN. Case series with cross-sectional analyses. SETTING. A regional hospital in Hong Kong. PATIENTS. Chinese children assessed between January 2006 and December 2010 at Tseung Kwan O Hospital for being overweight or obese. MAIN OUTCOME MEASURES. The demographics, anthropometric data, acanthosis nigricans status, and biochemical results were analysed. RESULTS. A total of 543 overweight/obese children were studied with 64% being boys and 29% had insulin resistance. Adolescents aged 12 to 18 years, compared with children aged 5 to 11 years, were more likely to have acanthosis nigricans (63% vs 47%; P<0.001) and insulin resistance (37% vs 25%; P=0.005). Compared with overweight children, those who were obese were more likely to have the two conditions: acanthosis nigricans (59% vs 44%; P=0.005) and insulin resistance (35% vs 19%; P=0.001). Compared with those without acanthosis nigricans, those with the condition had significantly higher mean values for systolic blood pressures (P<0.001), 2-hour post-oral glucose tolerance test glucose level (P=0.021), fasting insulin level (P<0.001), homeostasis model of assessment-insulin resistance (P<0.001), fasting triglyceride level (P<0.001), and alanine aminotransferase level (P=0.002), but a lower high-density lipoprotein cholesterol level (P<0.001). Those with acanthosis nigricans were also more likely to have insulin resistance (P<0.001), hypertension (P=0.021), fatty liver (P=0.001), and abnormal glucose homeostasis (P=0.003). CONCLUSION. Obese Chinese children and adolescents with acanthosis nigricans had a higher chance of having insulin resistance and cardiometabolic co-morbidities. Acanthosis nigricans is an important clinical feature warranting early attention and evaluation to facilitate timely interventions and monitoring.

Entities:  

Keywords:  Acanthosis nigricans; Child; Obesity

Mesh:

Year:  2014        PMID: 24762331     DOI: 10.12809/hkmj134071

Source DB:  PubMed          Journal:  Hong Kong Med J        ISSN: 1024-2708            Impact factor:   2.227


  6 in total

1.  Prevalence of Acanthosis nigricans and Related Factors in Iranian Obese Children.

Authors:  Fatemeh Sayarifard; Azadeh Sayarifard; Bahar Allahverdi; Sara Ipakchi; Mastaneh Moghtaderi; Bahareh Yaghmaei
Journal:  J Clin Diagn Res       Date:  2017-07-01

Review 2.  Acanthosis nigricans in obese adolescents: prevalence, impact, and management challenges.

Authors:  Hak Yung Ng
Journal:  Adolesc Health Med Ther       Date:  2016-12-16

3.  Association of Acanthosis Nigricans and Insulin Resistance in Indian Children and Youth - A HOMA2-IR Based Cross-Sectional Study.

Authors:  T M Nithun; P S S Ranugha; Jayadev B Betkerur; Veeranna Shastry
Journal:  Indian Dermatol Online J       Date:  2019 May-Jun

4.  Prevalence of acanthosis nigricans and its association with physical activity in adolescents - School-based analytical cross-sectional study from Kochi, Kerala.

Authors:  Remya Sudevan; S Vijay Kumar; Clint Sunny; Nanditha Sunand; Anu Vasudevan; Sonu K S; Apsy P V
Journal:  J Family Med Prim Care       Date:  2021-11-29

5.  Impact of Weight Reduction on Thyroid Function and Nonalcoholic Fatty Liver among Egyptian Adolescents with Obesity.

Authors:  Mona Karem Amin; Ahmed Ibrahim Ali; Hesham Elsayed
Journal:  Int J Endocrinol       Date:  2022-03-29       Impact factor: 3.257

6.  Determination of Child Waist Circumference Cut Points for Metabolic Risk Based on Acanthosis Nigricans, the Children's Healthy Living Program.

Authors:  Ashley B Yamanaka; James D Davis; Lynne R Wilkens; Eric L Hurwitz; Marie K Fialkowski; Jonathan Deenik; Rachael T Leon Guerrero; Rachel Novotny
Journal:  Prev Chronic Dis       Date:  2021-06-24       Impact factor: 4.354

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.